Edition:
United Kingdom

Lonza Group AG (LONN.S)

LONN.S on Virt-X Level 1

262.40CHF
2:27pm GMT
Change (% chg)

CHF5.30 (+2.06%)
Prev Close
CHF257.10
Open
CHF257.60
Day's High
CHF262.70
Day's Low
CHF257.40
Volume
150,399
Avg. Vol
301,071
52-wk High
CHF270.80
52-wk Low
CHF144.69

Select another date:

Thu, Nov 2 2017

BRIEF-Lonza ‍expands offerings for early phase biopharmaceutical drug development​

* Says ‍expands service offerings for early phase biopharmaceutical drug development​ Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

Lonza buys U.S. clinical manufacturing site from Shire

ZURICH Lonza Group is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire PLC, the Swiss pharmaceutical ingredients group said on Tuesday without giving the purchase price.

Lonza buys U.S. clinical manufacturing site from Shire

ZURICH, Oct 3 Lonza Group is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire PLC, the Swiss pharmaceutical ingredients group said on Tuesday without giving the purchase price.

UPDATE 2-Lonza outlines 2022 targets, shares hit record highs

ZURICH, July 26 Swiss pharmaceutical supplier Lonza Group AG set out ambitious growth targets and beat market expectations for first-half core profit, sending its shares more than 6 percent higher on Wednesday.

Lonza confirms 2017 outlook, outlines new 2022 targets

ZURICH, July 26 Swiss pharmaceutical supplier Lonza Group AG on Wednesday confirmed its 2017 outlook and outlined new targets through to 2022.

BRIEF-Lonza H1 sales 15.1 percent up to CHF 2,323 million

* Lonza delivers strong performance in first half 2017 and sets a strong foundation for continued attractive mid-term growth

BRIEF-Lonza says received regulatory approval for Capsugel acquisition

* Says lonza has received all regulatory approvals to move forward with acquisition of Capsugel

Select another date: